Parkinson’s patients are receiving a new investigational treatment after a successful study at the University of Wisconsin–Madison helped demonstrate the cell therapy’s safety in non-human primates and refine the method for its delivery. Now, the biotechnology company running the trial is reporting encouraging results.
Aspen Neuroscience recently announced they would enroll a third group of patients in their trial, called ASPIRO. The ASPIRO trial is referred to as Phase 1/2a, a stage designed to evaluate an investigational treatment’s safety and most effective dose in humans.
The patients already enrolled in the trial are safely tolerating the treatment, in which new brain cells, called neurons, are grown from the patients’ own cells and grafted into key parts of the brain. Their doctors have noted improvement in patients’ Parkinson’s symptoms, potentially providing promise for people living with this debilitating neurological disease.
Read the full story here: https://news.wisc.edu/parkinsons-treatment-tested-at-uw-showing-promise-in-first-clinical-trial/